

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

NCI-H322

RRID:CVCL_1556

Type: Cell Line

Proper Citation

RRID:CVCL_1556

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1556

Proper Citation: RRID:CVCL_1556

Description: Cell line NCI-H322 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:2386953](#), [PMID:2388294](#), [PMID:3335022](#), [PMID:7972006](#), [PMID:8806092](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:11416159](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H322

Synonyms: H322, H-322, H322T, NCI-H322T, NCIH322T, NCI-322, NCIH322

Cross References: BTO:BTO_0003007, CLO:CLO_0008083, EFO:EFO_0006691, CLDB:cl3655, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-5806, BioGRID_ORCS_Cell_line:525, BioSample:SAMN03471699, BioSample:SAMN03471740, BioSample:SAMN03473287, BioSample:SAMN10987678, cancercellines:CVCL_1556, ChEMBL-

Cells:CHEMBL3307405, ChEMBL-Targets:CHEMBL614573, CLS:305839, Cosmic:687822, Cosmic:801589, Cosmic:844830, Cosmic:876143, Cosmic:903571, Cosmic:917976, Cosmic:929972, Cosmic:932922, Cosmic:934547, Cosmic:980962, Cosmic:1028935, Cosmic:1032434, Cosmic:1146913, Cosmic:1152500, Cosmic:1239903, Cosmic:1802317, Cosmic:1870261, Cosmic:1891884, Cosmic:2042867, Cosmic:2125250, Cosmic:2648438, Cosmic:2668312, DepMap:ACH-000837, ECACC:95111734, EGA:EGAS00001000610, GEO:GSM171876, GEO:GSM171877, GEO:GSM206490, GEO:GSM253358, GEO:GSM274757, GEO:GSM274758, GEO:GSM434333, GEO:GSM784245, GEO:GSM794282, GEO:GSM817070, GEO:GSM827434, GEO:GSM887426, GEO:GSM888506, GEO:GSM1374741, IARC_TP53:516, IGRhCellID:NCIH322, KCLB:90322, LiGeA:CCLE_305, LINCS_LDP:LCL-1798, PharmacDB:NCIH322_1105_2019, Progenetix:CVCL_1556, PubChem_Cell_line:CVCL_1556, Wikidata:Q54908033

ID: CVCL_1556

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260920T004616+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H322.

Warning: Discontinued: ATCC; CRL-5806

Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: KCLB; 90322

Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. Cell reports. Medicine, 6(7), 102235.

Mizusaki S, et al. (2025) NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors. *Cancer immunology, immunotherapy* : CII, 74(7), 211.

Xiao C, et al. (2025) RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy. *Cancer letters*, 634, 218062.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Branco H, et al. (2025) Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. *International journal of cancer*, 156(9), 1756.

Huang HY, et al. (2024) Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *Journal of hazardous materials*, 477, 135105.

Sun H, et al. (2024) TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT. *iScience*, 27(6), 109869.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. *Cell chemical biology*, 31(12), 2069.

Aboukassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. *Cell reports*, 42(9), 113104.

DeBlasi JM, et al. (2023) Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. *Cancer research*, 83(12), 1953.

Kennedy PR, et al. (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. *Frontiers in immunology*, 14, 1060905.

Kwon M, et al. (2022) Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. *Cancer research communications*, 2(10), 1197.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. *Cancer cell*, 40(2), 136.

Cooke M, et al. (2021) FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma. *Cell reports*, 37(5), 109905.

Orre LM, et al. (2019) SubCellBarCode: Proteome-wide Mapping of Protein Localization and Relocalization. *Molecular cell*, 73(1), 166.

Lee HH, et al. (2019) Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. *Cancer cell*, 36(2), 168.

Kang YP, et al. (2019) Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. *eLife*, 8.

Liang CJ, et al. (2019) SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control. *Cell reports*, 28(6), 1511.

Huang R, et al. (2018) Identification of potential diagnostic and prognostic biomarkers in non-small cell lung cancer based on microarray data. *Oncology letters*, 15(5), 6436.